Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Sutro Biopharma (STRO) over the last 6 years, with Q3 2025 value amounting to $84.9 million.

  • Sutro Biopharma's Shares Outstanding (Diluted Average) rose 344.47% to $84.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.9 million, marking a year-over-year increase of 344.47%. This contributed to the annual value of $76.8 million for FY2024, which is 2770.06% up from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Shares Outstanding (Diluted Average) is $84.9 million, which was up 344.47% from $84.6 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Shares Outstanding (Diluted Average) registered a high of $84.9 million during Q3 2025, and its lowest value of $46.1 million during Q2 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $62.7 million, with a median of $60.3 million in 2023.
  • Per our database at Business Quant, Sutro Biopharma's Shares Outstanding (Diluted Average) soared by 4158.48% in 2021 and then soared by 182.37% in 2022.
  • Sutro Biopharma's Shares Outstanding (Diluted Average) (Quarter) stood at $46.1 million in 2021, then grew by 10.02% to $50.7 million in 2022, then increased by 18.57% to $60.2 million in 2023, then rose by 27.7% to $76.8 million in 2024, then grew by 10.47% to $84.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $84.9 million for Q3 2025, versus $84.6 million for Q2 2025 and $83.1 million for Q1 2025.